 |
|
Adding radioimmunotherapy to chemo may help patients with lymphoma
June 04, 2007Patients treated for follicular lymphoma, a slow-growing type of non-Hodgkin's lymphoma, may benefit from chemotherapy followed by radioimmunotherapy, according to a University of Pittsburgh Medical Center (UPMC) study presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago and published as Abstract 8005 in the ASCO proceedings.
Over 90 percent of study patients responded completely to the treatment and since only a short-course of chemotherapy was used, side effects were limited and well-tolerated. Radioimmunotherapy was delivered through the use of a radiolabeled monoclonal antibody specifically designed to kill lymphoma cells with the help of a radioactive atom.
"We found that adding a radioactive monoclonal antibody to standard chemotherapy helped lymphoma patients achieve a higher complete response rate. We hope that this will translate into long-lasting remissions," said Samuel Jacobs, M.D., lead investigator and associate director for clinical investigations at the University of Pittsburgh Cancer Institute and UPMC Cancer Centers.
In the study, a radiolabeled monoclonal antibody called ibritumomab tiuxetan (IT) was added to CHOP-R, a standard multi-drug regimen for follicular lymphoma that consists of cyclophosphamibe, doxorubicin, vincristine, prednisone and rituximab. Investigators reported on 50 patients treated with CHOP-R, examined their responses and then treated them with IT. Sixty-eight percent of the patients had a complete response to treatment with CHOP-R. This percentage increased to 96 percent after treatment with IT.
The complete response rate was determined by both conventional CT and the use of PET, or positron emission tomography-a scan that measures abnormal molecular cell activity. PET was used to determine which patients had an early complete disease response after treatment with chemotherapy alone and after treatment with IT. The researchers found that five out of 16 patients who had a positive PET scan after the initial chemotherapy phase of treatment relapsed. Of the 34 patients whose early PET scans were negative, none have relapsed to-date.
"We were surprised to find that PET was a useful tool in determining those patients who were at highest risk for their diseases to relapse. Our next step is to compare the tumor characteristics of the patients who relapsed to those who had an early complete response," said Dr. Jacobs.
University of Pittsburgh Schools of the Health Sciences
In the study, a radiolabeled monoclonal antibody called ibritumomab tiuxetan (IT) was added to CHOP-R, a standard multi-drug regimen for follicular lymphoma that consists of cyclophosphamibe, doxorubicin, vincristine, prednisone and rituximab. Investigators reported on 50 patients treated with CHOP-R, examined their responses and then treated them with IT. Sixty-eight percent of the patients had a complete response to treatment with CHOP-R. This percentage increased to 96 percent after treatment with IT.
The complete response rate was determined by both conventional CT and the use of PET, or positron emission tomography-a scan that measures abnormal molecular cell activity. PET was used to determine which patients had an early complete disease response after treatment with chemotherapy alone and after treatment with IT. The researchers found that five out of 16 patients who had a positive PET scan after the initial chemotherapy phase of treatment relapsed. Of the 34 patients whose early PET scans were negative, none have relapsed to-date.
"We were surprised to find that PET was a useful tool in determining those patients who were at highest risk for their diseases to relapse. Our next step is to compare the tumor characteristics of the patients who relapsed to those who had an early complete response," said Dr. Jacobs.
University of Pittsburgh Schools of the Health Sciences
Novel treatments show improvements in survival and response rates for leukemia and lymphoma
The use of dexamethasone early in the treatment of children with acute lymphoblastic leukemia, the most common type of childhood cancer, may help reduce the risk of relapse.
New study shows potential to treat or prevent viral cancers
A new study, presented at the SNM 55th Annual Meeting, shows that radioimmunotherapy (RIT) targeting viral antigens offers a novel option to treat-or even prevent-many viral cancers by targeting cancer cells expressing viral antigens or infected cells before they convert into malignancy.
Every patient is unique: Individualized therapies for non-Hodgkin's lymphoma
Positron emission tomography (PET) could be an important tool for identifying non-Hodgkin's lymphoma patients who are likely to respond well to treatment with 90 ibritumomab tiuxetan (IT)-the first radioimmunotherapy treatment approved for use by the U.S. Food and Drug Administration, said researchers at SNM's 55th Annual Meeting.
Einstein scientists treat cancer as an infectious disease -- with promising results
Researchers at the Albert Einstein College of Medicine of Yeshiva University have shown for the first time that cancers can be successfully treated by targeting the viruses that cause them.
New treatment option breaks Leukemia's resistance to chemotherapy, radiation therapy
German researchers set out to outwit cancer tumor cells that have become resistant to chemotherapy or radiation therapy and ended up expanding therapeutic applications of radionuclides in fighting leukemia.
More Radioimmunotherapy Current Events and Radioimmunotherapy News Articles
 |
Cancer Radioimmunotherapy: Present and Future by Pietro Riva (Author) Published more than 20 years after the pioneering work of Koler and Milstein, the first researchers to put monoclonal antibodies at the disposal of physicians, this book represents an update of the investigations devoted to the utilization of these new biological probes, conjugated to suitable radioisotopes, for the treatment of different solid and hematological tumors. Much progress has been made since the original findings of monoclonal antibodies, but several problems have to be resolved before this particular therapeutic approach can be applied extensively. Nevertheless some specific protocols, described in the book, look promising. In particular the results recorded in hematological malignancies, in ovarian cancer, and in brain tumors, show similar results as recorded in most kinds... |
 |
Radioimmunotherapy of Cancer by Abrams/Fritzber (Author) Reference surveying a breadth of topics on the evolving developments in radiation therapy. Provides treatment on radiolabeled antibody therapy. Reviews dosimetric principles and dosimetry of radioimmunotherapy in the targeting and delivery of radiation. Describes tumor architectures. Outlines constructs for radionuclide delivery. For oncologists. |
|
Radioimmunotherapy extends thyroid Ca survival.(Metabolic Disorders)(Disease/Disorder overview): An article from: Family Practice News by Heidi Splete (Author) This digital document is an article from Family Practice News, published by Thomson Gale on December 1, 2006. The length of the article is 658 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Radioimmunotherapy extends thyroid Ca survival.(Metabolic Disorders)(Disease/Disorder overview) Author: Heidi Splete Publication: Family Practice News (Magazine/Journal) Date: December 1, 2006 Publisher: Thomson Gale Volume: 36 Issue: 23 Page: 14(1) Article Type: Disease/Disorder overview Distributed by Thomson... | |
|
Idec starts shipping new cancer drug; Biotech: Zevalin is first radioimmunotherapy to reach the market. (Tech Talk).(Brief Article)(Statistical Data Included): ... An article from: San Diego Business Journal by Marion Webb (Author) This digital document is an article from San Diego Business Journal, published by CBJ, L.P. on April 1, 2002. The length of the article is 635 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Idec starts shipping new cancer drug; Biotech: Zevalin is first radioimmunotherapy to reach the market. (Tech Talk).(Brief Article)(Statistical Data Included) Author: Marion Webb Publication: San Diego Business Journal (Magazine/Journal) Date: April 1, 2002 Publisher: CBJ, L.P. Volume: 23 Issue: 13 Page: 8(1) Article Type: Brief Article, Statistical Data... | |
|
Synthesis of Functional Derivatives of B12 H122- Anion for Boron Neutron Capture Therapy, Radiodiagnostics and Radioimmunotherapy (Comprehensive Summaries of Uppsala Dissertations, 527) by Igor Sivaev (Author) | |
|
Investigational Studies Highlight Potential Utility of Zevalin Radioimmunotherapy in Stem Cell Transplantation for Non-Hodgkin's Lymphoma.: An article from: BIOTECH Patent News by Gale Reference Team (Author) This digital document is an article from BIOTECH Patent News, published by Biotech Patent News on June 1, 2008. The length of the article is 634 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser. Citation Details Title: Investigational Studies Highlight Potential Utility of Zevalin Radioimmunotherapy in Stem Cell Transplantation for Non-Hodgkin's Lymphoma. Author: Gale Reference Team Publication: BIOTECH Patent News (Newsletter) Date: June 1, 2008 Publisher: Biotech Patent News Volume: 22 Issue: 6 Distributed by Gale, a part of Cengage... | |
 |
Targeted Radionuclide Tumor Therapy: Biological Aspects by Torgny Stigbrand (Editor), Jorgen Carlsson (Editor), Gregory P. Adams (Editor) The last three decades have provided opportunities to explore the potential of treating malignant diseases with antibodies or other targeting molecules labelled with nuclides. The expanding array of new targeting molecules (recombinant antibodies or peptides) may increase the therapeutic efficacy. The title of this book "Targeted Radionuclide Tumor Therapy – Biological aspects" was selected to reinforce the concept that a major focus was devoted to understanding the biological effects of targeting and radiation. Furthermore, our rapidly expanding knowledge of low dose-rate effects, different types of cell death, autosensitization and the increasingly likely existence of cancer stem cells suggests to us that even more efficient approaches in targeting might be possible in the future.... |
 |
Hodgkin's and Non-Hodgkin's Lymphoma (Cancer Treatment and Research) by John P. Leonard (Editor), Morton Coleman (Editor) Over recent years, there has been a dramatic increase in knowledge of the biology of the lymphomas which has been accompanied by the emergence of new treatments that offer both improvements in efficacy and reduction in toxicity. Molecular profiling of tumor tissue and other new advances have led to a better understanding of the genetic basis of lymphoma, identification of new therapeutic targets, and potentially valuable prognostic information. Monoclonal antibody therapies, radioimmunoconjugates and other new agents such as proteosome inhibitors are providing important new treatment options for patients. In this volume, an internationally recognized group of experts provides a comprehensive overview of the biology, pathology, standard treatments, and novel approaches in management of... |
 |
Systemic Radiotherapy with Monoclonal Antibodies: Options and Problems (Recent Results in Cancer Research) by Marie-Luise Sautter-Bihl (Editor), Heiner Bihl (Editor), Michael Wannenmacher (Editor) This text is concerned with various options and problems in systemic radiotherapy with monoclonal antibodies. Topics covered include high dose radioimmunotherapy in malignant lymphoma and the treatment of patients with recurrent malignant gliomas with intratumoural radioimmunoconjugates. |
|
Improvement of Radioimmunotherapy in Ovarian Cancer: An Experimental Approach by Els Kievit (Author) |
| © 2009 BrightSurf.com |